FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175127908> ?p ?o ?g. }

• W3175127908 abstract "Objectives: To determine the safety and efficacy of canagliflozin in Polycystic Ovary Syndrome (PCOS) patients with insulin resistance (IR) and investigate whether canagliflozin was non-inferiority to metformin in PCOS patients with IR. Methods: A randomized open-label study (ratio 1:1) was conducted in the department of endocrinology, Shanghai Tenth people’s Hospital between July 2019 and March 2021. PCOS women aged 18-45 years with IR were enrolled and randomly assigned to either canagliflozin 100 mg (n = 32) or metformin 1500-2000 mg (n = 35) daily for 12 weeks. The primary outcome was the changes in HOMA-IR before and after 12 weeks treatment. The secondary outcome were the changes in anthropometric, body composition, menstrual frequency, hormonal and metabolic parameters. Results: A total of 53 subjects in the canagliflozin (n=27) and metformin group (n=26) have completed follow-up. Both canagliflozin (5.4±4.1 vs. 3.2±1.9; P=0.001) and metformin (4.7±3.5 vs. 3.6±3.0; P=0.009) can significantly improve HOMA-IR after 12 weeks in PCOS patients with IR. There was no significant difference in the changes of HOMA-IR (canagliflozin: −2.3 ± 3.2 vs. metformin: -1.4 ± 2.4; P = 0.222) between the two groups. According to a secondary endpoint analysis, the canagliflozin group resulted in significantly low uric acid than the metformin group. The changes in anthropometric, body composition, menstrual frequency, sex hormone and other metabolic parameters were comparable between two groups. Gastrointestinal reaction (including nausea, vomiting and Diarrhea) (57.14 %) and pruritus vulvae (6.25%) were the main adverse events in the metformin group and Canagliflozin group, respectively. There were none serious adverse events in both groups. Conclusion: Our study showed that canagliflozin was not significantly inferior to metformin in PCOS patients with IR, which suggested SGLT2 inhibitor should be considered as an effective drug in the treatment of patients with PCOS. Disclosure M. Cai: None. Y. Zhang: None. S. Qu: None. M. Zhang: None. Funding National Natural Science Foundation of China (81601269)" @default.
• W3175127908 created "2021-07-05" @default.
• W3175127908 creator A5041005462 @default.
• W3175127908 creator A5049155438 @default.
• W3175127908 creator A5076869458 @default.
• W3175127908 creator A5082110834 @default.
• W3175127908 date "2021-06-01" @default.
• W3175127908 modified "2023-09-25" @default.
• W3175127908 title "132-LB: The Safety and Efficacy of Canagliflozin in Women with Polycystic Ovary Syndrome: A Randomized Control Trial" @default.
• W3175127908 doi "https://doi.org/10.2337/db21-132-lb" @default.
• W3175127908 hasPublicationYear "2021" @default.
• W3175127908 type Work @default.
• W3175127908 sameAs 3175127908 @default.
• W3175127908 citedByCount "2" @default.
• W3175127908 countsByYear W31751279082022 @default.
• W3175127908 countsByYear W31751279082023 @default.
• W3175127908 crossrefType "journal-article" @default.
• W3175127908 hasAuthorship W3175127908A5041005462 @default.
• W3175127908 hasAuthorship W3175127908A5049155438 @default.
• W3175127908 hasAuthorship W3175127908A5076869458 @default.
• W3175127908 hasAuthorship W3175127908A5082110834 @default.
• W3175127908 hasConcept C126322002 @default.
• W3175127908 hasConcept C134018914 @default.
• W3175127908 hasConcept C168563851 @default.
• W3175127908 hasConcept C2777180221 @default.
• W3175127908 hasConcept C2777391703 @default.
• W3175127908 hasConcept C2777451236 @default.
• W3175127908 hasConcept C2779306644 @default.
• W3175127908 hasConcept C2780323712 @default.
• W3175127908 hasConcept C2780580376 @default.
• W3175127908 hasConcept C3018442814 @default.
• W3175127908 hasConcept C555293320 @default.
• W3175127908 hasConcept C71924100 @default.
• W3175127908 hasConcept C90924648 @default.
• W3175127908 hasConceptScore W3175127908C126322002 @default.
• W3175127908 hasConceptScore W3175127908C134018914 @default.
• W3175127908 hasConceptScore W3175127908C168563851 @default.
• W3175127908 hasConceptScore W3175127908C2777180221 @default.
• W3175127908 hasConceptScore W3175127908C2777391703 @default.
• W3175127908 hasConceptScore W3175127908C2777451236 @default.
• W3175127908 hasConceptScore W3175127908C2779306644 @default.
• W3175127908 hasConceptScore W3175127908C2780323712 @default.
• W3175127908 hasConceptScore W3175127908C2780580376 @default.
• W3175127908 hasConceptScore W3175127908C3018442814 @default.
• W3175127908 hasConceptScore W3175127908C555293320 @default.
• W3175127908 hasConceptScore W3175127908C71924100 @default.
• W3175127908 hasConceptScore W3175127908C90924648 @default.
• W3175127908 hasIssue "Supplement_1" @default.
• W3175127908 hasLocation W31751279081 @default.
• W3175127908 hasOpenAccess W3175127908 @default.
• W3175127908 hasPrimaryLocation W31751279081 @default.
• W3175127908 hasRelatedWork W1835582227 @default.
• W3175127908 hasRelatedWork W2022955668 @default.
• W3175127908 hasRelatedWork W2055600249 @default.
• W3175127908 hasRelatedWork W2102089120 @default.
• W3175127908 hasRelatedWork W2162054361 @default.
• W3175127908 hasRelatedWork W2744240433 @default.
• W3175127908 hasRelatedWork W2904480208 @default.
• W3175127908 hasRelatedWork W3028840175 @default.
• W3175127908 hasRelatedWork W4240163782 @default.
• W3175127908 hasRelatedWork W4246690683 @default.
• W3175127908 hasVolume "70" @default.
• W3175127908 isParatext "false" @default.
• W3175127908 isRetracted "false" @default.
• W3175127908 magId "3175127908" @default.
• W3175127908 workType "article" @default.